Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Breast 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

pembrolizumab 247Nivolumab 144Cyclophosphamide 137Cisplatin 137Paclitaxel 115Carboplatin 111Gemcitabine 100Radiotherapy 86Dexamethasone 84Docetaxel 79Ipilimumab 70atezolizumab 68Doxorubicin 63Fluorouracil 60Blood Specimen Collection 60Bevacizumab 59Etoposide 55fludarabine 54Rituximab 54Oxaliplatin 52Prednisone 51Lenalidomide 51Surveys and Questionnaires 50Cetuximab 47Standard of Care 46Capecitabine 46Radiosurgery 44Magnetic Resonance Spectroscopy 44lenvatinib 43durvalumab 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Ranitidine × 1 year × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡